Domestic Reference Pricing Would’ve Cut Launch Prices 18%-30%

By John Wilkerson / September 24, 2021 at 5:32 PM

Medicare would have saved 18% to 30% on newly launched drugs from 2015 to 2019 if it had used domestic reference pricing to control prices, and domestic reference prices for most drugs were even above the prices suggested by the Institute for Clinical and Economic Review, according to a report by West Health Policy Center, the University of Pittsburg and the University of California, San Diego.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.